• Aliases: 2C4, rhuMAb-2C4
    • A humanized recombinant mAb directed against the extracellular dimerization domain of the HER2
    • FDA approved for HER2–positive breast cancer
    • Recommended dose: A loading dose of 840 mg IV infusion (over 60 minutes); a maintenance dose of 420 mg IV infusion (over 30–60 minutes) every 3 weeks; approved to be given in combination with trastuzumab and docetaxel
    • Half-life: 18 days
    • Common side effects: Diarrhea, fatigue, neutropenia, rash, nausea/vomiting, stomatitis, embryo–fetal toxicity/cardiotoxicity (US box warning)
    Other topics in Targeted and Immunotherapy Agents